AGMB — AgomAb Therapeutics NV
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2020932 ·
Belgium
Last close
$9.22
Market Cap
$454.07M
52W High
$17.82
52W Low
$7.97
ADV30
186,429
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 290,923,000 | 221,588,000 | 25,547,000 |
| Dec 2025 | 0 | — | -16,527,000 | -17,401,000 | 153,706,000 | 86,418,000 | 22,804,000 |
| Sep 2025 | — | — | — | — | 165,631,000 | 129,585,000 | 18,700,000 |
| Dec 2024 | 0 | — | -11,814,000 | -11,732,000 | 206,358,000 | 171,459,000 | 18,277,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,609,000
Investing CF
$-30,367,000
Financing CF
$81,829,000
CapEx
$-363,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-181,714,000
Inventory
—
Receivables
$4,085,000
ST Investments
$30,096,000
EBIT TTM
$-29,423,000
Pretax Income TTM
$-29,129,000
Interest Exp TTM
$-294,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -59,275,000 | -62,547,000 | 153,706,000 | 22,804,000 | 130,902,000 | -51,741,000 |
| Dec 2024 | 0 | -48,021,000 | -46,267,000 | 206,358,000 | 18,277,000 | 188,081,000 | -46,828,000 |
| Dec 2023 | 0 | -31,190,000 | -11,390,000 | 171,259,000 | 19,824,000 | 151,435,000 | -24,592,000 |
| Dec 2022 | 0 | -22,634,000 | -8,142,000 | 100,995,000 | 34,747,000 | 66,248,000 | -18,967,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.07
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TECX | Tectonic Therapeutic, Inc. | $444.75M | $22.75 | — |
| AUTL | Autolus Therapeutics plc | $471.11M | $1.77 | — |
| EDIT | Editas Medicine, Inc. | $436.17M | $2.84 | — |
| ENTX | Entera Bio Ltd. | $432.85M | $2.50 | — |
| ALLO | Allogene Therapeutics, Inc. | $483.69M | $1.40 | — |
News headlines (Yahoo Finance, 1h cache)
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
2026-10-08 20:05 · Yahoo
Agomab stock jumps on positive trial data
2026-10-01 13:27 · Yahoo
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
2026-09-14 20:05 · Yahoo
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
2026-09-11 20:05 · Yahoo
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
2026-08-10 20:07 · Yahoo
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
2026-08-06 20:01 · Yahoo
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?
2026-07-02 20:06 · Yahoo
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
2026-06-23 20:05 · Yahoo
Agomab to Participate in Upcoming Conferences
2026-05-14 11:30 · Yahoo
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
2026-04-23 22:14 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-10-09 8:01:30 | 2026-10-08 | Epstein David R | Dir | P - Purchase | 8.9 | 5000 | 44500 |
| 2026-10-07 8:47:17 | 2026-10-06 | Kemula Pierre Thadee Victor | CFO | P - Purchase | 8.59 | 10000 | 85940 |
| 2026-10-07 8:57:36 | 2026-10-05 | Epstein David R | Dir | P - Purchase | 8.64 | 10000 | 86350 |
| 2026-10-07 8:06:35 | 2026-10-05 | Knotnerus Tim Jasper | CEO | P - Purchase | 8.58 | 11000 | 94380 |